Sarah Romano appointed as CFO of Vicarious Surgical for Medical Buyer
Vicarious Surgical Inc. has recently appointed Sarah Romano as their new Chief Financial Officer (CFO), effective starting April 1, 2025. Romano brings with her a wealth of experience in financial leadership, particularly in capital markets, with a track record of driving growth and creating value in the healthcare sector through various successful fundraising and M&A initiatives.
Adam Sachs, Co-Founder, and CEO of Vicarious Surgical, expressed excitement about the addition of Sarah Romano to their team, highlighting her strategic financial acumen as a valuable asset to the company. The anticipation is that Romano’s expertise and vision will play a crucial role in achieving financial objectives and overall success for Vicarious Surgical.
Sarah Romano shared her enthusiasm about joining the Vicarious Surgical team during a period of palpable energy and momentum as the company prepares for its first clinical use cases later in the year. She expressed her eagerness to contribute her experience towards ensuring financial strength to reach milestones and future objectives.
Romano’s most recent role was as the CFO of Entero Therapeutics, where she was responsible for overseeing financial strategy, operations, compliance, and successfully securing funding and executing product in-licensing partnerships. Prior to this, at Kiora Pharmaceuticals, Romano played a key role in securing substantial funding and driving M&A activities through due diligence and integration processes. Earlier in her career, Romano held roles of increasing responsibility, including corporate controller, involving tasks such as budget reviews, financial forecasting, internal controls oversight, and SEC reporting.
Sarah Romano holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross, showcasing her strong educational background in finance and accounting.
In other company news, HeartBeam reported a net loss of USD 4.9 million in the fourth quarter of 2024, indicating some financial challenges for the organization. On a different note, Kestra Medical Technologies successfully closed underwriters OAO in their recent IPO, reflecting a positive milestone for the company as they move forward in their financial journey.
These developments in the financial landscape of various companies highlight the importance of strong financial leadership and strategic oversight, showcasing the critical role that CFOs play in driving growth, value creation, and overall success in the healthcare sector and beyond.
